Mindfulness-based stress reduction for women diagnosed with breast cancer.


Journal

The Cochrane database of systematic reviews
ISSN: 1469-493X
Titre abrégé: Cochrane Database Syst Rev
Pays: England
ID NLM: 100909747

Informations de publication

Date de publication:
27 03 2019
Historique:
pubmed: 28 3 2019
medline: 18 4 2019
entrez: 28 3 2019
Statut: epublish

Résumé

Breast cancer is the most common cancer in women. Diagnosis and treatment may drastically affect quality of life, causing symptoms such as sleep disorders, depression and anxiety. Mindfulness-based stress reduction (MBSR) is a programme that aims to reduce stress by developing mindfulness, meaning a non-judgmental, accepting moment-by-moment awareness. MBSR seems to benefit patients with mood disorders and chronic pain, and it may also benefit women with breast cancer. To assess the effects of mindfulness-based stress reduction (MBSR) in women diagnosed with breast cancer. In April 2018, we conducted a comprehensive electronic search for studies of MBSR in women with breast cancer, in the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, and two trial registries (World Health Organization's International Clinical Trials Registry Platform (WHO ICTRP) and ClinicalTrials.gov). We also handsearched relevant conference proceedings. Randomised clinical trials (RCTs) comparing MBSR versus no intervention in women with breast cancer. We used standard methodological procedures expected by Cochrane. Using a standardised data form, the review authors extracted data in duplicate on methodological quality, participants, interventions and outcomes of interest (quality of life, fatigue, depression, anxiety, quality of sleep, overall survival and adverse events). For outcomes assessed with the same instrument, we used the mean difference (MD) as a summary statistic for meta-analysis; for those assessed with different instruments, we used the standardised mean difference (SMD). The effect of MBSR was assessed in the short term (end of intervention), medium term (up to 6 months after intervention) and long term (up to 24 months after intervention). Fourteen RCTs fulfilled our inclusion criteria, with most studies reporting that they included women with early breast cancer. Ten RCTs involving 1571 participants were eligible for meta-analysis, while four studies involving 185 participants did not report usable results. Queries to the authors of these four studies were unsuccessful. All studies were at high risk of performance and detection bias since participants could not be blinded, and only 3 of 14 studies were at low risk of selection bias. Eight of 10 studies included in the meta-analysis recruited participants with early breast cancer (the remaining 2 trials did not restrict inclusion to a certain cancer type). Most trials considered only women who had completed cancer treatment.MBSR may improve quality of life slightly at the end of the intervention (based on low-certainty evidence from three studies with a total of 339 participants) but may result in little to no difference up to 6 months (based on low-certainty evidence from three studies involving 428 participants). Long-term data on quality of life (up to two years after completing MBSR) were available for one study in 97 participants (MD 0.00 on questionnaire FACT-B, 95% CI -5.82 to 5.82; low-certainty evidence).In the short term, MBSR probably reduces fatigue (SMD -0.50, 95% CI -0.86 to -0.14; moderate-certainty evidence; 5 studies; 693 participants). It also probably slightly reduces anxiety (SMD -0.29, 95% CI -0.50 to -0.08; moderate-certainty evidence; 6 studies; 749 participants), and it reduces depression (SMD -0.54, 95% CI -0.86 to -0.22; high-certainty evidence; 6 studies; 745 participants). It probably slightly improves quality of sleep (SMD -0.38, 95% CI -0.79 to 0.04; moderate-certainty evidence; 4 studies; 475 participants). However, these confidence intervals (except for short-term depression) are compatible with both an improvement and little to no difference.In the medium term, MBSR probably results in little to no difference in medium-term fatigue (SMD -0.31, 95% CI -0.84 to 0.23; moderate-certainty evidence; 4 studies; 607 participants). The intervention probably slightly reduces anxiety (SMD -0.28, 95% CI -0.49 to -0.07; moderate-certainty evidence; 7 studies; 1094 participants), depression (SMD -0.32, 95% CI -0.58 to -0.06; moderate-certainty evidence; 7 studies; 1097 participants) and slightly improves quality of sleep (SMD -0.27, 95% CI -0.63 to 0.08; moderate-certainty evidence; 4 studies; 654 participants). However, these confidence intervals are compatible with both an improvement and little to no difference.In the long term, moderate-certainty evidence shows that MBSR probably results in little to no difference in anxiety (SMD -0.09, 95% CI -0.35 to 0.16; 2 studies; 360 participants) or depression (SMD -0.17, 95% CI -0.40 to 0.05; 2 studies; 352 participants). No long-term data were available for fatigue or quality of sleep.No study reported data on survival or adverse events. MBSR may improve quality of life slightly at the end of the intervention but may result in little to no difference later on. MBSR probably slightly reduces anxiety, depression and slightly improves quality of sleep at both the end of the intervention and up to six months later. A beneficial effect on fatigue was apparent at the end of the intervention but not up to six months later. Up to two years after the intervention, MBSR probably results in little to no difference in anxiety and depression; there were no data available for fatigue or quality of sleep.

Sections du résumé

BACKGROUND
Breast cancer is the most common cancer in women. Diagnosis and treatment may drastically affect quality of life, causing symptoms such as sleep disorders, depression and anxiety. Mindfulness-based stress reduction (MBSR) is a programme that aims to reduce stress by developing mindfulness, meaning a non-judgmental, accepting moment-by-moment awareness. MBSR seems to benefit patients with mood disorders and chronic pain, and it may also benefit women with breast cancer.
OBJECTIVES
To assess the effects of mindfulness-based stress reduction (MBSR) in women diagnosed with breast cancer.
SEARCH METHODS
In April 2018, we conducted a comprehensive electronic search for studies of MBSR in women with breast cancer, in the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, and two trial registries (World Health Organization's International Clinical Trials Registry Platform (WHO ICTRP) and ClinicalTrials.gov). We also handsearched relevant conference proceedings.
SELECTION CRITERIA
Randomised clinical trials (RCTs) comparing MBSR versus no intervention in women with breast cancer.
DATA COLLECTION AND ANALYSIS
We used standard methodological procedures expected by Cochrane. Using a standardised data form, the review authors extracted data in duplicate on methodological quality, participants, interventions and outcomes of interest (quality of life, fatigue, depression, anxiety, quality of sleep, overall survival and adverse events). For outcomes assessed with the same instrument, we used the mean difference (MD) as a summary statistic for meta-analysis; for those assessed with different instruments, we used the standardised mean difference (SMD). The effect of MBSR was assessed in the short term (end of intervention), medium term (up to 6 months after intervention) and long term (up to 24 months after intervention).
MAIN RESULTS
Fourteen RCTs fulfilled our inclusion criteria, with most studies reporting that they included women with early breast cancer. Ten RCTs involving 1571 participants were eligible for meta-analysis, while four studies involving 185 participants did not report usable results. Queries to the authors of these four studies were unsuccessful. All studies were at high risk of performance and detection bias since participants could not be blinded, and only 3 of 14 studies were at low risk of selection bias. Eight of 10 studies included in the meta-analysis recruited participants with early breast cancer (the remaining 2 trials did not restrict inclusion to a certain cancer type). Most trials considered only women who had completed cancer treatment.MBSR may improve quality of life slightly at the end of the intervention (based on low-certainty evidence from three studies with a total of 339 participants) but may result in little to no difference up to 6 months (based on low-certainty evidence from three studies involving 428 participants). Long-term data on quality of life (up to two years after completing MBSR) were available for one study in 97 participants (MD 0.00 on questionnaire FACT-B, 95% CI -5.82 to 5.82; low-certainty evidence).In the short term, MBSR probably reduces fatigue (SMD -0.50, 95% CI -0.86 to -0.14; moderate-certainty evidence; 5 studies; 693 participants). It also probably slightly reduces anxiety (SMD -0.29, 95% CI -0.50 to -0.08; moderate-certainty evidence; 6 studies; 749 participants), and it reduces depression (SMD -0.54, 95% CI -0.86 to -0.22; high-certainty evidence; 6 studies; 745 participants). It probably slightly improves quality of sleep (SMD -0.38, 95% CI -0.79 to 0.04; moderate-certainty evidence; 4 studies; 475 participants). However, these confidence intervals (except for short-term depression) are compatible with both an improvement and little to no difference.In the medium term, MBSR probably results in little to no difference in medium-term fatigue (SMD -0.31, 95% CI -0.84 to 0.23; moderate-certainty evidence; 4 studies; 607 participants). The intervention probably slightly reduces anxiety (SMD -0.28, 95% CI -0.49 to -0.07; moderate-certainty evidence; 7 studies; 1094 participants), depression (SMD -0.32, 95% CI -0.58 to -0.06; moderate-certainty evidence; 7 studies; 1097 participants) and slightly improves quality of sleep (SMD -0.27, 95% CI -0.63 to 0.08; moderate-certainty evidence; 4 studies; 654 participants). However, these confidence intervals are compatible with both an improvement and little to no difference.In the long term, moderate-certainty evidence shows that MBSR probably results in little to no difference in anxiety (SMD -0.09, 95% CI -0.35 to 0.16; 2 studies; 360 participants) or depression (SMD -0.17, 95% CI -0.40 to 0.05; 2 studies; 352 participants). No long-term data were available for fatigue or quality of sleep.No study reported data on survival or adverse events.
AUTHORS' CONCLUSIONS
MBSR may improve quality of life slightly at the end of the intervention but may result in little to no difference later on. MBSR probably slightly reduces anxiety, depression and slightly improves quality of sleep at both the end of the intervention and up to six months later. A beneficial effect on fatigue was apparent at the end of the intervention but not up to six months later. Up to two years after the intervention, MBSR probably results in little to no difference in anxiety and depression; there were no data available for fatigue or quality of sleep.

Identifiants

pubmed: 30916356
doi: 10.1002/14651858.CD011518.pub2
pmc: PMC6436161
doi:

Types de publication

Journal Article Meta-Analysis Research Support, N.I.H., Extramural Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

CD011518

Subventions

Organisme : NCCIH NIH HHS
ID : R24 AT001293
Pays : United States

Références

Trials. 2007 Jun 07;8:16
pubmed: 17555582
Psychiatry Res. 2011 Jan 30;191(1):36-43
pubmed: 21071182
J Clin Oncol. 2013 Sep 1;31(25):3119-26
pubmed: 23918953
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
J Clin Oncol. 2013 Feb 20;31(6):782-93
pubmed: 23319686
Psychooncology. 2009 Dec;18(12):1261-72
pubmed: 19235193
Cancer. 1999 Mar 1;85(5):1186-96
pubmed: 10091805
J Behav Med. 2014 Apr;37(2):185-95
pubmed: 23184061
Psychiatry Res. 1989 May;28(2):193-213
pubmed: 2748771
Psychooncology. 2015 Aug;24(8):885-93
pubmed: 25132206
Nurs Econ. 2015 Jul-Aug;33(4):210-8, 232
pubmed: 26477119
J Clin Epidemiol. 2014 Jan;67(1):100-7
pubmed: 24125895
Biol Res Nurs. 2013 Jan;15(1):37-47
pubmed: 22084404
Aust N Z J Psychiatry. 2002 Apr;36(2):246-50
pubmed: 11982548
Psychooncology. 2016 Jul;25(7):750-9
pubmed: 27193737
Complement Ther Clin Pract. 2012 Nov;18(4):221-6
pubmed: 23059436
Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S467-72
pubmed: 22588767
Med J Islam Repub Iran. 2015 Feb 08;29:175
pubmed: 26034728
Complement Ther Med. 2016 Jun;26:1-10
pubmed: 27261975
J Clin Oncol. 2006 Feb 20;24(6):848-55
pubmed: 16418496
J Psychosom Res. 1999 May;46(5):437-43
pubmed: 10404478
Acta Oncol. 2013 Feb;52(2):336-44
pubmed: 23282113
J Consult Clin Psychol. 2017 Apr;85(4):397-402
pubmed: 28230391
Ann Surg Oncol. 2012 Feb;19(2):373-8
pubmed: 21913014
J Clin Oncol. 2012 Apr 20;30(12):1335-42
pubmed: 22430268
Acta Oncol. 2015 May;54(5):712-9
pubmed: 25752972
Sleep. 2011 May 01;34(5):601-8
pubmed: 21532953
PLoS One. 2016 May 16;11(5):e0155431
pubmed: 27182821
Support Care Cancer. 2013 Aug;21(8):2107-15
pubmed: 23455455
Cancer. 2015 Apr 15;121(8):1231-40
pubmed: 25537522
Psychol Health Med. 2017 Jan;22(1):94-109
pubmed: 26853191
J Clin Oncol. 2018 Feb 20;36(6):563-571
pubmed: 29328860
Trials. 2016 Apr 22;17(1):209
pubmed: 27101823
Br J Psychiatry. 2012 Feb;200(2):97-106
pubmed: 22297588
Cancer. 2015 Feb 1;121(3):476-84
pubmed: 25367403
Oncol Nurs Forum. 2014 May;41(3):241-53
pubmed: 24650832
Cancer Med. 2017 May;6(5):1108-1122
pubmed: 28421677
Eur J Cancer. 2013 Apr;49(6):1365-73
pubmed: 23265707
Biol Res Nurs. 2015 Jul;17(4):393-404
pubmed: 25882604
J Clin Oncol. 2016 Aug 20;34(24):2827-34
pubmed: 27247219
Chin J Cancer Res. 2014 Feb;26(1):12-6
pubmed: 24653622
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
Qual Life Res. 2014 Feb;23(1):229-37
pubmed: 23765449
Integr Cancer Ther. 2013 Sep;12(5):404-13
pubmed: 23362338
Iran J Cancer Prev. 2014 Fall;7(4):184-96
pubmed: 25628839
Int J Behav Med. 2012 Dec;19(4):535-42
pubmed: 21931958
Breast Cancer Res Treat. 2012 Jan;131(1):99-109
pubmed: 21901389
Asian Pac J Cancer Prev. 2014;15(5):2109-14
pubmed: 24716942
Biol Res Nurs. 2014 Oct;16(4):429-37
pubmed: 24477514
BMC Complement Altern Med. 2013 Oct 02;13:248
pubmed: 24088535
Cochrane Database Syst Rev. 2019 Mar 27;3:CD011518
pubmed: 30916356
J Psychosom Res. 2003 Jan;54(1):85-91
pubmed: 12505559
J Clin Epidemiol. 2004 Sep;57(9):898-910
pubmed: 15504633
J Clin Oncol. 2016 Oct 1;34(28):3390-9
pubmed: 27325850
Psychooncology. 2013 May;22(5):1180-5
pubmed: 22592966
J Pain Symptom Manage. 2017 Jan;53(1):85-95
pubmed: 27720794
Psychother Psychosom Med Psychol. 2011 Jul;61(7):328-32
pubmed: 21755487
J Behav Med. 2012 Feb;35(1):86-94
pubmed: 21506018
Menopause. 2011 Jun;18(6):611-20
pubmed: 21372745
Stat Med. 1998 Dec 30;17(24):2815-34
pubmed: 9921604
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
Occup Med (Lond). 2014 Jul;64(5):393-4
pubmed: 25005549
Biol Res Nurs. 2014 Oct;16(4):438-47
pubmed: 24486564
Lancet Oncol. 2011 Feb;12(2):160-74
pubmed: 21251875
JAMA. 2008 Sep 17;300(11):1350-2
pubmed: 18799450
J Clin Epidemiol. 2009 Oct;62(10):1006-12
pubmed: 19631508
Breast Cancer. 2016 Jul;23(4):568-76
pubmed: 25820148
Acta Oncol. 2017 Dec;56(12):1665-1676
pubmed: 28686520
Breast Cancer Res Treat. 2015 Dec;154(3):509-20
pubmed: 26567010

Auteurs

Lisa K Schell (LK)

Cochrane Haematological Malignancies, Department I of Internal Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH